GDF15 and systemic sclerosis: A team of authors from the University of Colorado demonstrated significantly elevated plasma levels of GDF-15 in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH) compared to SSc patients without PAH.